Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

894 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
On-treatment lipoprotein components and risk of cerebrovascular events in the Treating to New Targets study.
van den Bogaard B, van den Born BJ, Fayyad R, Waters DD, DeMicco DA, LaRosa JC, Kastelein JJ, Holme I; Treating to New Targets investigators. van den Bogaard B, et al. Among authors: kastelein jj. Eur J Clin Invest. 2011 Feb;41(2):134-42. doi: 10.1111/j.1365-2362.2010.02387.x. Epub 2010 Sep 27. Eur J Clin Invest. 2011. PMID: 20868450 Clinical Trial.
Elevated remnant-like particles in heterozygous familial hypercholesterolemia and response to statin therapy.
de Sauvage Nolting PR, Twickler MB, Dallinga-Thie GM, Buirma RJ, Hutten BA, Kastelein JJ; Examination of Probands and Relatives in Statin Studies with Familial Hypercholesterolemia (ExPRESS) Study Group. de Sauvage Nolting PR, et al. Among authors: kastelein jj. Circulation. 2002 Aug 13;106(7):788-92. doi: 10.1161/01.cir.0000025586.89221.4b. Circulation. 2002. PMID: 12176948 Clinical Trial.
The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy.
de Grooth GJ, Zerba KE, Huang SP, Tsuchihashi Z, Kirchgessner T, Belder R, Vishnupad P, Hu B, Klerkx AH, Zwinderman AH, Jukema JW, Sacks FM, Kastelein JJ, Kuivenhoven JA. de Grooth GJ, et al. Among authors: kastelein jj. J Am Coll Cardiol. 2004 Mar 3;43(5):854-7. doi: 10.1016/j.jacc.2003.08.056. J Am Coll Cardiol. 2004. PMID: 14998629 Free article.
894 results